32nd week of 2011 patent applcation highlights part 32 |
Patent application number | Title | Published |
20110195028 | MAGNETIC RESONANCE IMAGING AND/OR SPECTROSCOPY CONTRAST AGENTS AND METHODS OF USE THEREOF - The presently disclosed subject matter demonstrates that a spin state which has zero magnetic resonance signal, but an extremely long lifetime, can be used to store magnetization, which can then be recovered into an observable transition. Coupled with hyper-polarization techniques, this permits the preparation of a wide range of contrast agent molecules for use in magnetic resonance imaging (MRI) techniques that have long effective relaxation time. | 2011-08-11 |
20110195029 | FLUORESCENT EMULSION - The invention relates to a fluorescent emulsion, to its uses and to labelling reagents comprising it. | 2011-08-11 |
20110195030 | NANOPARTICLE COMPOSITIONS COMPRISING LIQUID OIL CORES - Nanocapsule and nanoemulsion particle compositions having improved physical and pharmacological properties are provided. The nanocapsule or nanoemulsion particle composition can comprise a pharmaceutically acceptable liquid oil phase, a surfactant, and optionally a co-surfactant. The liquid oil phase can comprise a monoglyceride, a diglyceride, a triglyceride, a propylene glycol ester, or a propylene glycol diester. In certain embodiments, the nanocapsule or nanoemulsion particle composition can be lyophilized and subsequently re-hydrated without increasing the mean particle size and/or adversely affecting the potency or efficacy of a therapeutic agent (e.g., paclitaxel) present in the nanocapsules or nanoemulsion particles. | 2011-08-11 |
20110195031 | METHODS FOR THE USE OF PROGESTOGEN AS A GLUCOCORTICOID SENSITIZER - Provided are methods and kits for administering progestogen as a glucocorticoid sensitizer to restore corticosteroid sensitivity or reverse the glucocorticoid insensitivity or enhance glucocorticoid sensitivity, in order to treat one or more glucocorticoid insensitivity related diseases or conditions. For example, these include methods for reversing the glucocorticoid insensitivity in a subject having no history of menstrual cycle-related exacerbation or allergy to self-hormones, particularly progesterone, such as premenstrual or perimenstrual deterioration in the symptoms, e.g., premenstrual worsening of atopic dermatitis or premenstrual exacerbations of asthma, and exhibiting relatively or totally refractory responses to glucocorticoid therapy, e.g., glucocorticoid resistance. The methods and kits provide for the administration of a sex hormone to the subject who is corticosteroid dependent or corticoid resistant or unresponsive or intolerant to corticosteroids. | 2011-08-11 |
20110195032 | Menthylcarboxamides and Their Use as Cooling Agents - Described is a new cooling agent represented by Structure I and compositions with known coolers having cooling properties and the application of Structure I in foodstuffs and chewing gum: | 2011-08-11 |
20110195033 | Automated Method and System for Introducing Molecular Iodine into Drinking Water - A system and method for delivering molecular iodine or any other substance into a pet's drinking water on a daily basis without exceeding the safe amount allowed for the pet. The present invention delivers a particular amount of molecular iodine into the pet water supply to achieve maximum benefit of I | 2011-08-11 |
20110195034 | AGENT FOR CUTANEOUS PHOTOPROTECTION AGAINST UVA/UVB RAYS - This invention describes a new agent for cutaneous photoprotection against UVA (I and II) and UVB radiation that contains an aqueous extract obtained from a plant in the Gramineae family from the Antarctic Continent ( | 2011-08-11 |
20110195035 | Ester Compounds For Use In Personal Care Products - The present invention relates to cosmetic and/or personal care formulations and/or compounds. In one embodiment, the present invention relates to ester compounds that can be used in various personal care formulations and/or compounds. In another embodiment, the present invention relates to branced ester compounds having a molecular weight of at least about 1,500 daltons that can be used in various personal care formulations and/or compounds. | 2011-08-11 |
20110195036 | SUNSCREEN COMPOSITIONS COMPRISING AN ULTRAVIOLET RADIATION-ABSORBING POLYMER - Aqueous compositions including a discontinuous oil phase containing an ultraviolet radiation-absorbing polymer stabilized in a continuous aqueous phase, an oil-gelling polymer, and which are substantially free of non-polymeric ultraviolet radiation-absorbers. | 2011-08-11 |
20110195037 | PERFUMING COMPOSITIONS AND USES THEREOF - A perfuming composition capable of prolonging the release of a perfuming component into the surrounding environment when applied on a surface. This composition utilizes hydrophobic block copolymers in the presence of high amounts of ethanol. The invention also relates to consumer articles containing such compositions. It finally provides methods for the perfuming of a surface and a method for increasing the long-lastingness of a perfuming component using these compositions. | 2011-08-11 |
20110195038 | COMPOUNDS HAVING SANDALWOOD ODORS - Sandalwood perfuming ingredients that are 2-[perhydro-trialkyl-2-naphthalenylidene]-1-propanol or propanal derivatives of the formula | 2011-08-11 |
20110195039 | HAIR BUILDING SOLID AGENT - A method of treating hair comprising applying a hair building solid agent for use on or with one or more of hair, skin and hair building solids for altering and/or maintaining the electrostatic charge of the hair and/or skin such that it has a substantially negative polarity. The method further comprises applying hair building solids to hair before and/or during and/or after applying the hair building solid agent. The hair building solid agent is applied as a spray on to the hair and/or skin and/or hair building solid. | 2011-08-11 |
20110195040 | METHOD FOR PREVENTING THE FORMATION OF ADHESIONS FOLLOWING SURGERY OR INJURY - Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH | 2011-08-11 |
20110195041 | ANTIMICROBIAL COMPOSITIONS - Provided are antimicrobial compositions including at least one biocide covalently bound to a polyurethane. The biocide moiety may comprise triclosan, a triclosan derivative, or a quaternary ammonium salt. Further provided are methods of reducing biofilm formation or microbial growth on a surface, the method including applying to the surface an antimicrobial composition including at least one biocide covalently attached to a polyurethane. | 2011-08-11 |
20110195042 | Compositions, Methods and Kits Useful for Treating a Respiratory Symptom - The present disclosure describes methods for enhancing an overall cooling sensation of an oral mucosa comprising administering a liquid composition comprising a thickening agent and/or a mucoadhesive polymer, a non-menthol coolant; and contacting the oral mucosa with the liquid composition. The disclosure also describes the liquid compositions. | 2011-08-11 |
20110195043 | Dimeric Smac Mimetics - The invention provides small molecule mimics of the Smac peptide that are dimers or dimer-like compounds having two binding domains connected by a linker These compounds are useful to promote apoptosis. The invention includes pharmaceutical compositions comprising such compounds and methods to use them to treat conditions including cancer and autoimmune disorders. | 2011-08-11 |
20110195044 | Hepatitis C Virus Inhibitors - The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2011-08-11 |
20110195045 | Methods, agents and peptides for inducing an immune response to matrix metalloproteinase-2 expressing tumors - The present invention relates to enhancing, modulating or stimulating the immune response to MMP-2 expressing tumors, including melanoma, and to the modulation and application of immune modulators and MMP-2 peptides for melanoma or other MMP-2 expressing tumor vaccines. The invention provides methods and means to activate an effective response to MMP-2 expressing tumors and modulate the ability of MMP-2 to skew CD4+ T cell responses toward that of T | 2011-08-11 |
20110195046 | ERYTHROPOIETIN AMELIORATES CHEMOTHERAPY-INDUCED TOXICITY IN VIVO - A method of reducing organ toxicity in a subject being administered a cytotoxic agent comprising concurrently administering with the cytotoxic agent erythropoietin (EPO), the EPO being administered in an amount effective to reduce pulmonary toxicity caused by the cytotoxic agent. | 2011-08-11 |
20110195047 | ONCOSTATIN M AS PROMOTER OF IMMUNOSTIMULATORY ACTIVITY OF HUMAN EPITHELIAL CELLS - The invention relates to the use of oncostatin M (OSM), an OSM receptor (OSMR) agonist, or a combination of OSM or a OSMR agonist with an interferon type I; in the manufacture of a medicament for enhancing the immunostimulatory activity of epithelial cells in a human. | 2011-08-11 |
20110195048 | REGULATION OF LYMPHOCYTES AND USES THEREFOR - Compositions comprising TNF receptor super-family member 25 (TNFR25) agents, attenuate Treg activity and, by comparison with other TNFR members, only weakly costimulates T effector cell (Teff) activity. Alternatively spliced TNFR25 modulates the functional effects of TNFR25 signaling These agents have a wide therapeutic applicability in the treatment of diseases by modulating immune responses. In addition these agents can be used in conjunction with vaccines to enhance the immune response. | 2011-08-11 |
20110195049 | COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS - Described herein are compositions and methods for treating multiple sclerosis. In particular, described herein are compositions that include one or more dimebolins and/or pharmaceutically acceptable salts thereof and methods for using the compositions for treating multiple sclerosis. | 2011-08-11 |
20110195050 | USE OF A COMBINATION OF MYXOMA VIRUS AND RAPAMYCIN FOR THERAPEUTIC TREATMENT - The present invention relates to therapeutic use of a combination of Myxoma virus, including in combination with rapamycin. Treatment with rapamycin enhances the ability of Myxoma virus to selectively infect cells that have a deficient innate anti-viral response, including cells that are not responsive to interferon. The combination of rapamycin and Myxoma virus can be used to treat diseases characterized by the presence of such cells, including cancer. The invention also relates to therapeutic use of Myxoma virus that does not express functional M135R. | 2011-08-11 |
20110195051 | USE OF BACTERIA OF THE GENUS TENACIBACULUM FOR QUORUM QUENCHING - Use of bacterial cells of the genus | 2011-08-11 |
20110195052 | BONE MATRIX COMPOSITIONS AND METHODS - The present invention provides methods of improving the osteogenic and/or chondrogenic activity of a bone matrix, e.g., a dermineralized bone matrix (DBM), by exposing the bone matrix to one or more treatments or conditions. In preferred embodiments the bone matrix is derived from human bone. The treatment or condition may alter the structure of the bone matrix and/or cleave one or more specific proteins. Cleavage may generate peptides or protein fragments that have osteoinductive, osteogenic, or chondrogenic activity. Preferred treatments include collagenase and various other proteases. The invention further provides improved bone and cartilage matrix compositions that have been prepared according to the inventive methods and methods of treatment using the compositions. The invention further provides methods of preparing, testing, and using the improved bone matrix compositions. On a assay comprises exposing relatively undifferentiated mesenchymal cells to a bone matrix composition and measuring expression of a marker characteristic of osteoblast or chondrocyte lineage(s). Increased expression of the marker relative to the level of the marker in cells that have been exposed to a control matrix (e.g., an inactivated or untreated matrix) indicates that the treatment or condition increased the osteogenic and/or chondrogenic activity of the bone matrix. Suitable cells include C2C12 cells. A suitable marker is alkaline phosphatase. The inventive methods increase the osteogenic and/or chondrogenic activity of human DBM when tested using this assay system. | 2011-08-11 |
20110195053 | Treatment of Non-Neuronal Cancer using HSV-1 Variants - A mutant herpes simplex virus which has been modified in the γ34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome. | 2011-08-11 |
20110195054 | Preparation And Use Of Stromal Cells For Treatment Of Cardiac Diseases - This invention is directed to the preparation and use of stromal cells for treatment of cardiac tissue. | 2011-08-11 |
20110195055 | Method and apparatus for holding cells - The present invention pertains to an apparatus for holding cells. The apparatus comprises a mechanism for incubating cells having a dynamically controlled environment in which the cells are grown, which are maintained in a desired condition and in which cells can be examined while the environment is dynamically controlled and maintained in the desired condition. The apparatus also comprises a mechanism for determining the state of the cells. The determining mechanism is in communication with the incubating mechanism. The present invention pertains to a method for holding cells. The method comprises the steps of incubating the cells in a dynamically controlled environment which is maintained in a desired condition and in which the cells can be examined while the environment is dynamically controlled and maintained in the desired condition. Additionally, there is the step of determining the state of the cells. | 2011-08-11 |
20110195056 | COMPOSITIONS COMPRISING HEPATOCYTE-LIKE CELLS AND USES THEREOF - The invention generally features methods for generating hepatocytes from a variety of pluripotent stem cells, including adipose mesenchymal stem cells, therapeutic compositions featuring such cells, and methods of using them for the treatment of subjects. | 2011-08-11 |
20110195057 | Growth Inhibition and Elimination of Methicillin-Resistant Staphylococcus Aureus by Lactic Acid Bacteria - The present invention relates to methicillin-resistant | 2011-08-11 |
20110195058 | CARDIOVASCULAR SUPPORT SUPPLEMENT AND COMPOSITIONS AND METHODS THEREOF - A cardiovascular support composition is provided comprising red yeast rice, Coenzyme-Q10, and phytosterols. A method for maintaining cardiovascular health is also provided comprising administering the composition comprising red yeast rice, Coenzyme-Q10, and phytosterols in a predefined dosage to an individual in need thereof. | 2011-08-11 |
20110195059 | Enzymatic Prevention and Control of Biofilm - The invention provides methods, compositions, and kits for removal of biofilms from surfaces. The methods described herein comprise simultaneous or sequential application of a perhydrolase enzyme and a mixture of other enzymes, such as proteases, glucanases, esterases, mannanases, phospholipases, cellulases, and/or amylases, to a biofilm on a surface, to effect removal of the biofilm. | 2011-08-11 |
20110195060 | PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydroiase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided. | 2011-08-11 |
20110195061 | COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN USING A MIXTURE OF FISH OIL AND FISH OIL DERIVED, CHOLINE BASED, PHOSPHOLIPID BOUND FATTY ACID MIXTURE INCLUDING POLYUNSATURATED EPA AND DHA - Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA wither alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form. | 2011-08-11 |
20110195062 | Mammalian Cytokines; Related Reagents and Methods - Nucleic acids encoding mammalian, e.g., primate, IL-ζ, purified IL-1ζ polypeptides and fragments thereof. Binding proteins, e.g., antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are provided. | 2011-08-11 |
20110195063 | Methods of Treating Ankylosing Spondylitis Using Anti-TNF Antibodies and Peptides of Human Tumor Necrosis Factor - Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided. | 2011-08-11 |
20110195064 | SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA - The invention provides methods and materials related to a gene expression-based survival predictor for diffuse large B cell lymphoma (DLBCL) patients. | 2011-08-11 |
20110195065 | Compositions and Methods for Diagnosing and Treating Cancer - The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor and inhibits growth of tumor cells. The present invention further provides a method of treating cancer, the method comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human NOTCH receptor protein and inhibits growth of tumor cells. | 2011-08-11 |
20110195066 | QUINOLINE INHIBITORS OF TYROSINE KINASE - The present invention relates to new quinoline inhibitors of tyrosine kinases, pharmaceutical compositions thereof, and methods of use thereof. | 2011-08-11 |
20110195067 | POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW AFFINITY FCy RECEPTORS - The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG | 2011-08-11 |
20110195068 | PD-1 ANTAGONISTS AND METHODS OF USE THEREOF - Compositions and methods for enhancing and/or prolonging the activation of T cells (i.e., increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation ad effector functions of T cells and/or promoting T cell survival) or overcoming T cell exhaustion and/or anergy are provided. Suitable compositions include PD-1 receptor antagonists that bind to and block the endogenous PD-1 receptor without triggering inhibitory signals from PD-1, or bind to and block PD-1 receptor ligands and preventing them from interacting with PD-1 receptors. Methods for using the PD-1 receptor antagonists to enhance immune responses in subjects in need thereof are provided. | 2011-08-11 |
20110195069 | INHIBITORS OF COMPLEMENT ACTIVATION - The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′) | 2011-08-11 |
20110195070 | DETECTION OF GRANULOSA-CELL TUMORS - A method of detecting a granulosa-cell tumor is described herein. The method involves detecting a mutation in a sample derived from a subject, indicative of substitution of tryptophan in place of cysteine at amino acid position 134 of FOXL2 protein. The mutation may be detected as a DNA mutation 402C>G in the FOXL2 gene. Methods for screening for a granulosa-cell tumor from a blood-based assay are provided, as well as methods for making a determination that an ovarian tumor is not a granulosa-cell tumor. Kits for granulosa-cell tumors are described, and a method of treating a granulosa-cell tumor are also described. | 2011-08-11 |
20110195071 | THERAPY-ENHANCING GLUCAN - This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection. | 2011-08-11 |
20110195072 | NON-NEUROENDOCRINE CANCER THERAPY - The present invention provides a method of selecting subjects suffering or being predisposed to suffering from a proliferative disease in non-neuroendocrine tissues for treatment with a Ret inhibitor. The present invention also provides Ret inhibitors as medicaments for subjects suffering or being predisposed to suffering from a proliferative disease in non-neuroendocrine tissues. | 2011-08-11 |
20110195073 | COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE - Compositions and methods for the stimulating, enhancing or promoting an immune response in a host are provided. One embodiment provides methods and compositions for stimulating, enhancing, or promoting an immune response in a host by administering an effective amount of a B7-H4 antagonist, preferably sH4 or variant thereof. Compositions of sH4 can be used to enhance an immune response to treat infection, cancer, or as part of a vaccine. | 2011-08-11 |
20110195074 | Ephrin Type-A Receptor 7 Protein - The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, for monitoring the effectiveness of treatment of bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, lung cancer, osteosarcoma, pancreatic cancer, prostate cancer, skin cancer, thyroid cancer or uterine cancer, including metastatic cancer, and for drug development. | 2011-08-11 |
20110195075 | USE OF A PNEUMOCOCCAL P4 PEPTIDE FOR ENHANCING OPSONOPHAGOCYTOSIS IN RESPONSE TO A PATHOGEN - Methods for enhancing opsonophagocytosis of a pathogen of interest are disclosed. The disclosed methods include administering to a subject an isolated P4 peptide, which including the amino acid sequence set forth as SEQ ID NO: 1 and optionally an isolated opsonic antibody or a fragment thereof that specifically binds to an antigen present of the surface of the pathogen of interest. In some examples isolated complement protein or a fragment thereof (for example, a C3a, C3b, iC3b, C3d, C4b, or C5a fragment of a complement protein) is also administering. Compositions contain isolated P4 peptide and one or more isolated opsonic antibodies or a fragment thereof that specifically binds to an antigen present of the surface of a pathogen of interest are also disclosed. In some examples, the compositions also isolated complement protein or fragment thereof, such as one or more of C3a, C3b, iC3b, C3d, C4b, or C5a. | 2011-08-11 |
20110195076 | THERAPEUTIC AGENT - The present invention relates to agents which modulate the effect of a RAMP (Receptor Activity Modifying Protein) protein on a Calcitonin Receptor Like Receptor (CRLR). Also included in the present invention are methods and uses of such agents and assays for identifying such agents. The agents of the present disclosure may be used in the treatment of, for example, cancer, obesity and other disorders. | 2011-08-11 |
20110195077 | METHODS AND COMPOSITIONS USING FGF23 FUSION PPOLYPEPTIDES - The present disclosure is directed to methods, kits and compositions for preventing or treating age-related conditions or metabolic disorders. The fusion polypeptides of the disclosure include FGF23 or an active fragment thereof. In one embodiment, the fusion polypeptide comprises (a) a polypeptide comprising fibroblast growth factor 23 (FGF23), or a functionally active variant or derivative thereof, wherein FGF23 has a mutation at one or more of the positions Q156, C206 and C244; and (b) either a modified Fc fragment having decreased affinity for Fc-gamma-receptor and/or increased serum half-life, or a polypeptide comprising at least one extracellular subdomain of a Klotho protein, or a functionally active variant or derivative thereof; and, optionally (c) a linker. The Klotho fusion proteins are useful in the treatment and prevention of a variety of age-related conditions and metabolic disorders. In another embodiment, the fusion polypeptide comprises a FGF (such as FGF23), or a functionally active variant or derivative thereof; and a modified Fc fragment, or a functionally active variant or derivative thereof. In various embodiments of the fusion polypeptides, FGF23 has mutations which decrease aggregation and protease-mediated cleavage. | 2011-08-11 |
20110195078 | TAT-BASED IMMUNOMODULATORY COMPOSITIONS AND METHODS FOR THEIR DISCOVERY AND USE - A method for identifying new immunomodulatory chemical entities (NICE) comprising reacting a candidate NICE with a Tat SH3 binding domain, identifying the bound candidate NICE and determining whether the candidate NICE induces monocytes to differentiate into dendritic cells (DC) or regulatory macrophages (AReg). In particular, the present invention relates to identifying NICE that are either immunostimulatory or immunosuppressive. | 2011-08-11 |
20110195079 | IMMUNIZATION PROTOCOL FOR DIRECTED EXPANSION AND MATURATION - A first antigen is administered to a subject to select progenitor B cells that are suitable for subsequent production of a desirable affinity-matured antibody, and then a second antigen is administered to stimulate the expansion of B cells that produce that affinity-matured antibody. An immunization protocol is used in which two different antigens are administered (usually in series, but in some embodiment simultaneously), where the first antigen elicits an efficient germline antibody response and the second antigen elicits an efficient and desired affinity-matured antibody response. | 2011-08-11 |
20110195080 | Compositions and Methods for Enhanced Somatostatin Immunogenicity in the Treatment of Growth Hormone and Insulin-Like Growth Factor One Deficiency - Compositions and methods are provided for treatment growth hormone and/or insulin-like growth factor 1 deficiency in a patient in need of such treatment. Compositions and methods include novel vaccines that provide immunogenicity for somatostatin and result in the increased release of endogenously produced growth hormone and/or insulin-like growth factor 1. | 2011-08-11 |
20110195081 | FOXM1 PEPTIDE AND MEDICINAL AGENT COMPRISING THE SAME - An objective of the present invention is to provide a means for enabling cancer immunotherapy that targets approximately 30% of various cancer patients that highly express forkhead box M1 (FOXM1) among the Japanese, by identifying FOXM1-derived peptides that can activate cancer cell-damaging human killer T cells by binding to HLA-A2. The present invention provides a peptide of (A) or (B) below:
| 2011-08-11 |
20110195082 | Multimeric Complexes of Antigens and an Adjuvant - The invention relates to a product which comprises a C4bp domain of a non-mammalian origin, particularly SEQ ID NO:1, SEQ ID NO:23 or SEQ ID NO:37, or a variant thereof, and an antigen. The product is desirably in the form of a fusion protein. The chicken C4bp domain of SEQ ID NO:1 and SEQ ID NO:23 is also described. Antigens include monomeric antigens such as malarial and influenza antigens. The C4bp domain provides for assembly of multimeric complexes of the antigen, or mixtures thereof. The complexes are useful as vaccines. | 2011-08-11 |
20110195083 | CYCLIC V3 PEPTIDES FOR ANTI HIV-1 VACCINE - Isolated cyclic polypeptides useful as vaccinations for the treatment/prevention of HIV are disclosed. An exemplary peptide comprises at least 18 consecutive amino acids of a V3 domain of gp120, starting at position 303 and ending at position 322, the positioning being according to a numbering of the V3 domain of gp120 in a HXB2 strain, wherein amino acids at position 303 and 322 are bonded. Vaccines comprising same and methods of treating AIDS using same are also disclosed. | 2011-08-11 |
20110195084 | Anti-HIV Vaccine Constructed Based on Amino Acid Mutations in Attenuated Live EIAV Vaccine - Provided are antigenic polypeptides of HIV envelope glycoproteins which are constructed based on amino acid mutation of attenuated live vaccine of Equine Infectious Anemia Virus, DNA constructions and recombinant virus vectors comprising polynucleotides encoding said polypeptides, antibodies against said polypeptides as well as uses thereof in preventing and treating HIV infection. Said antigenic polypeptides and vaccines can induce high titer neutralization antibodies against HIV in organism. | 2011-08-11 |
20110195085 | Methods of and Systems for Isolating Nutraceutical Products from Algae - A method of isolating nutraceuticals products from algae is provided. A method of isolating carotenoids and omega-3 rich oil from algae includes dewatering substantially intact algal cells to make an algal biomass and adding a first ethanol fraction to the algal biomass. The method also includes separating a first substantially solid biomass fraction from a first substantially liquid fraction comprising proteins and combining the first substantially solid biomass fraction with a second ethanol fraction. The method further includes separating a second substantially solid biomass fraction from a second substantially liquid fraction comprising polar lipids and combining the second substantially solid biomass fraction with a third ethanol solvent fraction. The method also includes separating a third substantially solid biomass fraction from a third substantially liquid fraction comprising neutral lipids, wherein the third substantially solid biomass fraction comprises carbohydrates and separating the neutral lipids into carotenoids and omega-3 rich oil. | 2011-08-11 |
20110195086 | 15-VALENT PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE VACCINE COMPOSITION - The present invention provides a multivalent immunogenic composition having 15 distinct polysaccharide-protein conjugates. Each conjugate consists of a capsular polysaccharide prepared from a different serotype of | 2011-08-11 |
20110195087 | COMBINATION VACCINE WITH WHOLE CELL PERTUSSIS - The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, whole cell pertussis and polio. The present invention also relates to inclusion of one or more antigens in the said combination vaccine, for protection against infections caused by | 2011-08-11 |
20110195088 | Porcine Reproductive and Respiratory Syndrome Isolates and Methods of Use - A method of predicting the virulence of a new or uncharacterized PRRS virus strain is provided wherein the strain is injected into swine and allowed to replicate for a period of from about 3-15 days. During this period, the rate of virus growth and/or the magnitude of viremia is determined, and this data is compared with a corresponding growth rate and/or viremia magnitude of a PRRS virus strain of known virulence, as a measure of the virulence of the new or uncharacterized strain. | 2011-08-11 |
20110195089 | COMPOSITIONS, METHODS, AND KITS FOR ENHANCING THE IMMUNOGENICITY OF PATHOGENIC ANTIGENS - The invention provides a method of enhancing the immunogenicity of pathogenic antigens by removing or disrupting intrachain disulfide bonds responsible for maintaining tertiary protein structure. Removal of one or more disulfide bonds can increase the titer of neutralizing antibodies to a pathogen (e.g., a bacterium, fungus, virus, or parasite). The invention also features vaccines, expression vectors, and methods for the manufacture and use thereof. | 2011-08-11 |
20110195090 | METHOD OF MAKING A VACCINE - The present invention provides a vaccine and method for making same which is effective to elicit a desired antibody against a target antigen comprising a primary immunogen and a secondary immunogen, wherein the primary immunogen is effective to elicit B cell receptors (BCRs) that are on the maturational pathway of the desired antibody and have an intermediate degree of somatic mutational diversity, and the secondary immunogen comprises an epitope of the desired target antibody and is effective to further diversify the BCRs sufficient to form mature BCRs having the identical or substantially identical sequence as the desired antibody. | 2011-08-11 |
20110195091 | Avian Influenza Virus Antigen, and Booster Immunization Method for Avian Influenza Vaccine in Combination with Mucosal Adjuvant Which is Effective Through Oral Administration - When ELISA antibody titer dropped in chickens intramuscularly inoculated with an oil vaccine, recombinant HA and NP antigens prepared using gene recombinant technology were orally administered in combination with synthetic oligo CpG as a mucosal adjuvant to the chickens. Even when the immune response induced with the oil vaccine was impaired, the antibody titer was re-induced by orally administering the recombinant HA and NP antigens, and synthetic CpG-ODN in combination. | 2011-08-11 |
20110195092 | LIVE ATTENUATED ALDOLASE-NEGATIVE BACTERIAL VACCINE - The present invention relates to live attenuated bacteria for use in a medicament. The invention also relates to vaccines based upon such bacteria useful for the prevention of microbial pathogenesis and to the use of such bacteria for the manufacture of a vaccine. Finally, the invention relates to methods for the preparation of such vaccines. | 2011-08-11 |
20110195093 | Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers - The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. | 2011-08-11 |
20110195094 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound. | 2011-08-11 |
20110195095 | INJECTABLE NANOPARTICULATE OLANZAPINE FORMULATIONS - Described are injectable formulations of nanoparticulate olanzapine that produce a prolonged duration of action upon administration, and methods of making and using such formulations. The injectable formulations comprise nanoparticulate olanzapine. | 2011-08-11 |
20110195096 | COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS - Compositions which include a corticosteroid in combination with an additional compound active in treatment of an inflammatory disorder are provided. | 2011-08-11 |
20110195097 | COMPOSITION AND DOSAGE FORM COMPRISING A PARTICLE FORMULATION AND SUSPENDING VEHICLE - A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent. | 2011-08-11 |
20110195098 | Porous, Dissolvable Solid Substrate and Surface Resident Coating Comprising Water Sensitive Actives - The present invention relates to personal care compositions, especially those personal care compositions in the form of a personal care article that is a porous dissolvable solid substrate. The porous dissolvable solid substrate has a surface resident coating comprising a water sensitive active that can deliver a consumer benefit. | 2011-08-11 |
20110195099 | PARTICULATE WAX COMPOSITES HAVING A CORE/SHELL STRUCTURE AND METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF - The invention relates to inorganic-organic composite particles having a core/shell structure, wherein the composite particles comprise an organically based core having at least one wax, and an inorganically based shell surrounding said core, and to a method for the production thereof and to the use thereof | 2011-08-11 |
20110195100 | LIP COMPOSITIONS COMPRISING GALVANIC PARTICULATES - Novel lip compositions are disclosed. The lip compositions comprise galvanic particulates and provide the following benefits: enhanced lip color, reduced fine lines and wrinkles, increased fullness, improved moisturization, smoothness, texture, and improved definition and lip contour. | 2011-08-11 |
20110195101 | Polysaccharide Capsules and Methods of Preparation - The present invention is directed to seamless capsules and methods for making seamless capsules having a high oil content as described herein. More specifically, the present invention is directed to seamless capsules, and methods for making seamless capsules, made from a process involving the steps of: (a) preparing an emulsion comprising oil, water, an emulsifier, and at least one of a water-soluble monovalent metal salt, polyvalent metal salt, and an acid, wherein said oil is present in an amount of at least 50% by weight of said emulsion; with the proviso that said emulsion does not contain marmelo mucilage; and (b) adding portions of said emulsion to an aqueous gelling bath comprised of at least one ionic polysaccharide thereby encapsulating said portions of said emulsion in a polysaccharide gel membrane, and optionally (c) drying the resulting capsules by removing water. | 2011-08-11 |
20110195102 | PEPTIDES USEFUL IN THE TREATMENT AND/OR CARE OF SKIN, MUCOUS MEMBRANES, SCALP AND/OR HAIR AND THEIR USE IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS - Peptides with general formula (I): R | 2011-08-11 |
20110195103 | COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING PSEUDOALTEROMONAS FERMENT EXTRACT - Cosmetic or dermopharmaceutical compositions containing | 2011-08-11 |
20110195104 | INTEGRATED ANTIMICROBIAL AND LOW FOULING MATERIALS - Cationic polymers hydrolyzable to zwitterionic polymers, monomers for making the cationic polymers, surfaces that include the polymers, and methods for making and using the cationic polymers and surfaces. The cationic polymers include counterions and/or hydrolyzable groups that release active agents. | 2011-08-11 |
20110195105 | Foam Cellular Matrix Impregnated With Anti-Microbial Active Agent For Use In Negative Pressure Wound Therapy Applications And Process For Producing The Same - A foam cellular matrix and process for making the matrix. The matrix is for use in negative pressure wound therapy (NPWT) applications. The matrix contains inorganic anti-microbial agent, which is added during foam generation. The elements mixed during foam generation comprise a polyol, a surfactant, a catalyst, water, an isocyanate, and the inorganic anti-microbial agent in the ratio of 0 to 6 parts inorganic anti-microbial agent to 100 parts polyol. | 2011-08-11 |
20110195106 | Decorin and Gliosis and Related System and Method - Brain stimulators are used to treat a variety of disorders, and their range of uses continues expand. However, one problem with long-term stimulation of neural tissue is the need to increase the stimulation parameters to continue to maintain the same clinical effect. This is thought to be due to local tissue reaction to the implanted foreign body. Because the implanted stimulator functions by means of contact with functional cells within the tissue, prevention of tissue reaction to the stimulator would make a significant improvement to the device's performance and longevity. | 2011-08-11 |
20110195107 | METHOD FOR MANUFACTURING A POROUS THREE-DIMENSIONAL SCAFFOLD USING POWDER FROM ANIMAL TISSUE, AND POROUS THREE-DIMENSIONAL SCAFFOLD MANUFACTURED BY SAME - The present invention provides a method for manufacturing a porous three-dimensional scaffold using animal tissue powder, comprising powdering an animal-derived tissue, decellularizing the animal-derived tissue before or after powdering it, or simultaneously with powdering it, and forming the decellularized animal-derived tissue powder into a porous three-dimensional scaffold by a particle leaching method. | 2011-08-11 |
20110195108 | ANTIVIRAL AGENT - An antiviral agent is provided which can inactivate a wide range of viruses. Products that include such an antiviral agent are also provided. | 2011-08-11 |
20110195109 | ADHESIVE SKIN PATCH AND PACKAGED PRODUCT - Provided is a patch | 2011-08-11 |
20110195110 | UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER - Pyrazole urea compounds, pharmaceutical compositions which contain them and methods for treating cancer using them. | 2011-08-11 |
20110195111 | AQUEOUS COMPOSITIONS AND METHODS - A method of forming an aqueous composition effective to produce an agent-specific effect on an agent-responsive chemical or biological system, when the composition is added to the system, is disclosed. The composition is formed by exposing an aqueous medium to a low-frequency, time-domain signal derived from the agent, until the aqueous medium acquires a detectable agent activity. Exemplary compositions are formed by exposure to a paclitaxel signal or a signal derived from a therapeutic oligonucleotide, such as GAPDH antisense RNA and PCSK9 antisense RNA. Also disclosed are methods for confirming the activity of the composition, and for preparing and testing the activity of the compositions. | 2011-08-11 |
20110195112 | USE OF PLANT-DERIVED RECOMBINANT GROWTH FACTORS IN SKIN CARE - Cosmetic and therapeutic compositions for skin care, containing a transgenic plant extract containing a growth factor, or a growth factor purified from transgenic plants, or a mixture of growth factors derived from transgenic plants as extracts or in purified form, for use in topical therapeutic and/or cosmetic applications. Importantly, this invention makes safer growth factors available for use for cosmetic and topical treatment. These growth factors do not carry the risk of unwanted contaminants and transmissible agents that can result from animals or animal cell based expression systems, and the recombinant growth factors that plant expression systems provide are post-translationally modified proteins. | 2011-08-11 |
20110195113 | VIRUS-LIKE PARTICLES COMPRISING COMPOSITE CAPSID AMINO ACID SEQUENCES FOR ENHANCED CROSS REACTIVITY - The present invention provides polypeptides having a composite amino acid sequence derived from a consensus sequence representing the capsid proteins of two or more circulating strains of a non-enveloped virus. In particular, the invention provides virus-like particles comprising at least one composite polypeptide. Such virus-like particles have antigenic epitopes of two or more circulating strains of a non-enveloped virus and produce an increase in antisera cross-reactivity to one or more circulating strains of the non-enveloped virus. Methods of making composite virus-like particles and vaccine formulations comprising composite virus-like particles are also disclosed. | 2011-08-11 |
20110195114 | TRANSDERMAL DELIVERY SYSTEMS FOR ACTIVE AGENTS - A delivery vehicle for topical pharmaceutical formulations that include a C2 to C4 alkanol, a polyalcohol, and a monoalkyl ether of diethylene glycol present in relative amounts sufficient to provide permeation enhancement of an active agent through mammalian dermal or mucosal surfaces. Preferably, the delivery vehicle as well as the formulations that contain it are substantially free of long-chain fatty alcohols, long-chain fatty acids and long-chain fatty esters in order to avoid potential undesirable odor and irritation effects caused by such compounds during use of the formulation. Without these additives, use of the formulations is facilitated and patient compliance is greater | 2011-08-11 |
20110195115 | HYDROPHILIC AMINO ACID-CONTAINING PREPARATION HAVING IMPROVED TASTE - The present invention provides a hydrophilic amino acid-containing preparation wherein the taste of the hydrophilic amino acid is improved without damaging the appearance, flavor, storage stability and so on. It is further intended to provide a hydrophilic amino acid-containing preparation in which quick release of the hydrophilic amino acid from the preparation is assured, if necessary. It is furthermore intended to provide a hydrophilic amino acid-containing preparation where a solid agent containing a hydrophilic amino acid is coated with a coating agent comprising a flavoring agent and a water-soluble high molecular material. | 2011-08-11 |
20110195116 | RATE MODULATED DELIVERY OF DRUGS FROM A COMPOSITE DELIVERY SYSTEM - This invention relates to a pharmaceutical dosage form for the delivery of at least one active pharmaceutical ingredient (API) or the pharmaceutically active salts and isomers thereof, to a desired absorption location of the human or animal body, preferably the gastrointestinal tract, in a predetermined rate-modulated manner. The dosage form is orally ingestible and is in the form of a multi-layered tablet preferably three layers and each layer includes an API or capsule containing a multiplicity of multi-layered granules. Each layer contains one or more APIs mixed or blended with at least one and preferably a matrix of polymers and, where appropriate, excipients, which, in use, inhibit release of an API in a region of the gastrointestinal tract other than the desired absorption location and, thus, facilitate release of the API in a rate controlled manner when in the desired absorption location. Methods of manufacturing said dosage form are further disclosed. | 2011-08-11 |
20110195117 | CONTROLLED RELEASE COMPOSITIONS OF ROPINIROLE - A novel oral controlled release pharmaceutical composition comprising a therapeutically effective amount of active substance, ropinirole or a pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) or hydrate(s) thereof, one or more controlled release agent(s), optionally one or more pharmaceutically acceptable excipient(s) and an extended release coating, wherein the said composition provides controlled release of the active agent with reduced initial burst release. | 2011-08-11 |
20110195118 | Process for Producing Oral Dosage Forms With Controlled Release - A process for producing solid oral dosage forms with controlled active ingredient release, comprising a mixture of
| 2011-08-11 |
20110195119 | CONTROLLED RELEASE METFORMIN FORMULATIONS - Sustained release pharmaceutical formulations comprising an antihyperglycemic drug or a pharmaceutically acceptable salt thereof are disclosed. The formulations provide therapeutic plasma levels of the antihyperglycemic drug to a human patient over a 24 hour period after administration. | 2011-08-11 |
20110195120 | Sustained Release Pharmaceutical Composition Containing Metformin Hydrochloride - A monolithic sustained-release pharmaceutical composition comprising a therapeutically effective dose of metformin hydrochloride as an active substance and a hydrophobic polymer and/or other hydrophobic material, wherein the metformin hydrochloride is released no more than forty percent in gastric fluid having pH 1.2 and is released no less than ninety percent eight to ten hours after administration in simulated intestinal fluid (phosphate buffer) having pH 6.8, and wherein the metformin hydrochloride displays a peak plasma concentration, a systemic bioavailability over time, and a residual plasma concentration twenty-four hours after administration of an oral dosage form of the pharmaceutical composition, so that the metformin hydrochloride concentration remains therapeutically effective and once daily administration of the pharmaceutical composition is sufficient to be therapeutically effective throughout a day. | 2011-08-11 |
20110195121 | CHRONOTHERAPEUTIC PHARMACEUTICAL DOSAGE FORM - This invention relates to a pharmaceutical dosage form for the phase-controlled and chronotherapeutic delivery of at least one and, preferably, several pharmaceutically active ingredients. The dosage form has a carrier platform which,—preferably, is a polymer having known biodegradable characteristics. The platform may include a pharmaceutically active ingredient'which is released over a predetermined period of time as the platform polymer degrades. At least one pharmaceutically active ingredient in the form of a disc is embedded in the platform and, once the polymer of the platform has degraded, the disc is released and releases its ingredient in the same location as that of the platform or it travels to another region of the body where it releases its ingredient. | 2011-08-11 |
20110195122 | Extended Release Formulation - The invention is directed to an extended release formulation comprising pramipexole or a pharmaceutically acceptable salt thereof. | 2011-08-11 |
20110195123 | METHODS, COMPOSITIONS AND SYSTEMS FOR LOCAL DELIVERY OF DRUGS - Implantable medical device eluting drug locally and in prolonged period is provided, including several types of such a device, the treatment modes of implementation and methods of implantation. The device comprising of polymeric substrate, such as a matrix for example, that is used as the device body, and drugs, and in some cases additional scaffolding materials, such as metals or additional polymers, and materials to enhance visibility and imaging. The selection of drug is based on the advantageous of releasing drug locally and in prolonged period, where drug is released directly to the extracellular matrix (ECM) of the diseased area such as tumor, inflammation, degeneration or for symptomatic objectives, or to injured smooth muscle cells, or for prevention. One kind of drug is the gene silencing drugs based on RNA interference (RNAi), including but not limited to si RNA, sh RNA, or antisense RNA/DNA, ribozyme and nucleoside analogs. The modes of implantation in some embodiments are existing implantation procedures that are developed and used today for other treatments, including brachytherapy and needle biopsy. In such cases the dimensions of the new implant described in this invention are similar to the original implant. Typically a few devices are implanted during the same treatment procedure. | 2011-08-11 |
20110195124 | PHASE-TRANSITION POLYMERIC MICRONEEDLES - This invention discloses a novel microneedle system, phase-transition microneedle patch, which overcomes all the limitations that existing microneedles encountered. The microneedle patch is formed of an integrated polymeric piece consisting of a microneedle array and a plate (called holding plate) on which the needles stand. The microneedles of the patch are hard and strong enough to penetrate epidermis at dry state but turn to be hydrogel state soft and permeable to hydrophilic agents when absorbing body fluid. The hydrogel state of the patch is a hydrophilic network held by physical or chemical cross-linking junctions. The pores of the network are opened up by body fluid for drugs and macromolecules to diffuse through. The polymeric materials used to form the microneedle patch have been used in the pharmaceutical field for years and have proven compatibility with the skin and with proteins. The drugs may be stored in the matrix of the microneedle array as well as the holding plate so that the requirement for high dose applications may be full filled. In addition, molding (casting) of this type of microneedle patch is simple, easy to achieve and needs no microfabrication systems and organic solvents. By a programmed molding (casting), the patch may be assembled in a layered structure with desired drug concentration in each layer, respectively. Due to this design, a programmed pulse or a zero order release of drugs may easily be achieved. In addition, delicate proteins loaded in the patch are kept in a dry and hydrophilic glassy state before being released, the most favored state for protein storage. Finally, during the swelling-based drug release, the microneedle patch increases their thickness gradually between the skin and the back cover (which holds the needles) lo create a sustained pressure to ensure good contact of the microneedles inside epidermis. | 2011-08-11 |
20110195125 | Nanoparticles For Drug Delivery To The Central Nervous System - The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt of the formula: | 2011-08-11 |
20110195126 | PEPTIDE-COATED NANOPARTICLES WITH GRADED SHELL COMPOSITIONS - A peptide-coated nanoparticle that includes a nanocrystal surrounded by a graded shell that is composed of at least two different semiconductor molecules. At least one peptide is attached to the surface of the graded shell to render the nanoparticle biocompatible. The nanocrystal core and graded shell are optionally annealed with ultra violet radiation prior to and/or after attachment of the peptide(s). | 2011-08-11 |
20110195127 | COMPOSITIONS AND METHODS FOR SILENCING APOLIPOPROTEIN B - The present invention provides compositions and methods for the delivery of interfering RNAs that silence APOB expression to liver cells. In particular, the nucleic acid-lipid particles provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo. The compositions of the present invention are highly potent, thereby allowing effective knock-down of APOB at relatively low doses. In addition, the compositions and methods of the present invention are less toxic and provide a greater therapeutic index compared to compositions and methods previously known in the art. | 2011-08-11 |